AHSAX — Alger Health Sciences Fund, Class A
Data updated: 2026-09-25
AHSAX — Alger Health Sciences Fund, Class A. 1.17% expense ratio · 5.25% max sales load · since 2002. Holdings, fees, performance and SEC filings.
AHSAX Fund Overview
AHSAX — Alger Health Sciences Fund, Class A is a US mutual fund managed by Alger Funds, categorised as United States Multi-Cap / All-Cap Growth Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Alger Funds
- Category: United States Multi-Cap / All-Cap Growth Health Care Equity
- Assets under management: $75.36M
- 1-year return: 53.1%
- Ticker: AHSAX
- SEC CIK: 0000003521
- SEC series ID: S000009164
- Share class ID: C000024915
AHSAX Investment Objective and Strategy
Alger Health Sciences Fund describes its objective and strategy as follows, from its latest prospectus filed with the SEC by Alger Funds.
Investment objective
Alger Health Sciences Fund seeks long-term capital appreciation.
Principal investment strategy
Fred Alger Management, Inc. believes companies undergoing Positive Dynamic Change offer the best investment opportunities. Positive Dynamic Change refers to companies realizing High Unit Volume Growth or companies undergoing Positive Lifecycle Change. High Unit Volume Growth companies are traditional growth companies experiencing, for example, significantly growing demand or market dominance. Positive Lifecycle Change companies are, for example, companies benefitting from regulatory change, a new product introduction or management change. Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of companies of any market capitalization that are engaged in the health sciences sector. Equity securities include common or preferred stocks that are listed on U.S.
or foreign exchanges. A company will be considered to be engaged in the health sciences sector if it derives at least 50% of its earnings or revenues from, or devotes at least 50% of its assets to, activities in any area of the health sciences sector, including health care services, pharmaceuticals, medical equipment and supplies and applied research and development. Such companies include, but are not limited to: hospitals, clinical test laboratories, convalescent and mental health care facilities, home care providers, and companies that supply services to any of the foregoing; companies involved in pharmaceuticals, biotechnology, biochemistry and diagnostics; and producers and manufacturers of medical, dental and optical supplies and equipment. The Fund's portfolio manager(s) may sell a stock when it reaches a target price, it fails to perform as expected, or other opportunities appear more attractive.
As a result, the Fund may engage in active trading of portfolio securities. The Fund can leverage, that is, borrow money to buy additional securities. By borrowing money, the Fund has the potential to increase its returns if the increase in the value of the securities purchased exceeds the cost of borrowing, including interest paid on the money borrowed. However, leverage also has the potential to magnify any decrease in the value of the purchased securities. The Fund can also invest in privately placed securities, which are securities acquired in non-public offerings for which there is no readily available market. The Fund can invest in foreign securities.
AHSAX Holdings
Top 10 holdings of Alger Health Sciences Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Dreyfus Treasury Obligations Cash Management | 6.51% |
| Impulse Dynamics Ireland | 4.65% |
| Merck & Company, Inc. | 4.18% |
| Welltower, Inc. | 4.12% |
| Johnson & Johnson | 4.06% |
| Thermo Fisher Scientific, Inc. | 4.00% |
| Bruker Corp. | 3.98% |
| Illumina, Inc. | 3.95% |
| Cvs Health Corp. | 3.67% |
| Unitedhealth Group, Inc. | 3.61% |
AHSAX Portfolio Allocation
Asset-class allocation of Alger Health Sciences Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 91.9% |
| Cash & Equivalents | 6.5% |
AHSAX Performance
Total returns for AHSAX (as of 2026-10-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 21.64% |
| 1 year | 53.06% |
| 3 years (annualised) | 10.58% |
| 5 years (annualised) | 5.90% |
AHSAX Risk Information
Risk metrics for AHSAX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 16.97%
AHSAX Costs and Fees
AHSAX costs about $117 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.17%
- Gross expense ratio: 1.17%
- Portfolio turnover: 289%
- Brokerage commissions: 32.15 bps of average net assets (SEC N-CEN)
AHSAX Cashflows
Over the 12 months to 2026-04, Alger Health Sciences Fund had net outflows of $20.90M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$924.72K |
| 2026-03 | −$1.40M |
| 2026-02 | −$826.83K |
| 2026-01 | −$1.63M |
| 2025-12 | −$2.06M |
| 2025-11 | −$910.82K |
AHSAX Debt Constituents
No individual debt constituents are reported in Alger Health Sciences Fund's latest SEC N-PORT filing.
AHSAX Prospectus and SEC Filings
Official Alger Health Sciences Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
- Prospectus (485BPOS) — filed 2025-02-26
- Prospectus supplement (497) — filed 2026-03-05
- Prospectus supplement (497) — filed 2025-03-04
- Portfolio holdings (N-PORT) — filed 2026-09-25
- Portfolio holdings (N-PORT) — filed 2026-06-26
- Portfolio holdings (N-PORT) — filed 2026-03-27
- Annual census (N-CEN) — filed 2026-01-14
- Annual census (N-CEN) — filed 2025-01-13
Related Funds
Other United States Multi-Cap / All-Cap Growth Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.